All Stories

  1. Clinical, economic and societal impact of antibiotic resistance

    Article • Expert Opinion on Pharmacotherapy, December 2014, Informa Healthcare

    Dr Steven Barriere

  2. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease

    Article • Diagnostic Microbiology and Infectious Disease, December 2014, Elsevier

    Dr Steven Barriere

  3. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

    Article • BMC Infectious Diseases, May 2014, Springer Science + Business Media

    Dr Steven Barriere

  4. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia

    Article • Infection and Drug Resistance, May 2014, Taylor & Francis

    Dr Steven Barriere

  5. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies

    Article • BMC Infectious Diseases, April 2014, Springer Science + Business Media

    Dr Steven Barriere

  6. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia

    Article • Future Microbiology, March 2014, Future Medicine

    Dr Steven Barriere

  7. Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival

    Article • Antimicrobial Agents and Chemotherapy, January 2014, ASM Journals

    Dr Steven Barriere

  8. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers

    Article • Journal of Thrombosis and Thrombolysis, October 2013, Springer Science + Business Media

    Dr Steven Barriere

  9. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia

    Article • International Journal of Antimicrobial Agents, October 2013, Elsevier

    Dr Steven Barriere

  10. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia

    Article • Diagnostic Microbiology and Infectious Disease, December 2012, Elsevier

    Dr Steven Barriere

  11. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections

    Article • Future Microbiology, December 2010, Future Medicine

    Dr Steven Barriere

  12. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies

    Article • Diagnostic Microbiology and Infectious Disease, October 2010, Elsevier

    Dr Steven Barriere

  13. Challenges in the Design and Conduct of Clinical Trials for Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia: An Industry Perspective

    Article • Clinical Infectious Diseases, August 2010, Oxford University Press (OUP)

    Dr Steven Barriere

  14. Single-Dose Pharmacokinetics and Tolerability of Telavancin in Elderly Men and Women

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, August 2010, Wiley

    Dr Steven Barriere

  15. Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double-Blind, Crossover Study in Healthy Subjects

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, February 2010, Wiley

    Dr Steven Barriere

  16. Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, January 2010, Wiley

    Dr Steven Barriere

  17. BACTEREMIC HOSPITAL-ACQUIRED PNEUMONIA CASES FROM THE ATTAIN STUDIES

    Article • CHEST Journal, October 2009, Elsevier

    Dr Steven Barriere

  18. Lack of Pharmacokinetic Drug Interactions Following Concomitant Administration of Telavancin with Aztreonam or Piperacillin/Tazobactam in Healthy Participants

    Article • The Journal of Clinical Pharmacology, July 2009, Wiley

    Dr Steven Barriere

  19. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures

    Article • The American Journal of Surgery, June 2009, Elsevier

    Dr Steven Barriere

  20. Cost-Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2008, Wiley

    Dr Steven Barriere

  21. Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

    Article • Clinical Infectious Diseases, June 2008, Oxford University Press (OUP)

    Dr Steven Barriere

  22. Protein Synthesis Inhibitors, Fluoroquinolones, and Rifampin for Biofilm Infections

    Article • August 2005, Taylor & Francis

    Dr Steven Barriere

  23. Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects

    Article • The Journal of Clinical Pharmacology, July 2004, Wiley

    Dr Steven Barriere

  24. Antimicrobial Therapy and Vaccines: By Victor L. Yu, Thomas C. Merigan, Jr., and Steven L. Barriere. Baltimore: Williams & Wilkins, 1999. 1460 pp

    Article • Clinical Infectious Diseases, December 1999, Oxford University Press (OUP)

    Dr Steven Barriere

  25. Mortality Risk Prediction in Sepsis

    Article • Critical Care Medicine, October 1995, Wolters Kluwer Health

    Dr Steven Barriere

  26. Challenges in Identification of Patient Candidates for Adjunctive Therapies in Sepsis

    Article • Journal of Infectious Disease Pharmacotherapy, June 1995, Taylor & Francis

    Dr Steven Barriere

  27. An overview of mortality risk prediction in sepsis

    Article • Critical Care Medicine, February 1995, Wolters Kluwer Health

    Dr Steven Barriere

  28. THE IMPACT OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1ra) ON THE HOSPITAL AND ICU LENGTH OF STAY OF PATIENTS WITH SEPSIS SYNDROME

    Article • Critical Care Medicine, January 1994, Wolters Kluwer Health

    Dr Steven Barriere

  29. Pharmacokinetics and pharmacodynamics of antimicrobial agents

    Article • Current Opinion in Infectious Diseases, December 1992, Wolters Kluwer Health

    Dr Steven Barriere

  30. The Economic Impact of HA-1A (Centoxin) Against Endotoxin

    Article • PharmacoEconomics, November 1992, Springer Science + Business Media

    Dr Steven Barriere

  31. Manual of Antibiotics and Infectious Diseases By John E. Conte, Jr., and Steven L. Barriere. 7th ed. Malvern, Pennsylvania: Lea & Febiger, 1992. 419 pp. $30.

    Article • Clinical Infectious Diseases, June 1992, Oxford University Press (OUP)

    Dr Steven Barriere

  32. Evaluation of new quinolones

    Article • Antimicrobic Newsletter, April 1992, Elsevier

    Dr Steven Barriere

  33. Update on new oral cephalosporins

    Article • Antimicrobic Newsletter, March 1992, Elsevier

    Dr Steven Barriere

  34. Antimicrobial therapy with the new fluoroquinolones

    Article • Current Opinion in Infectious Diseases, December 1991, Wolters Kluwer Health

    Dr Steven Barriere

  35. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects

    Article • Diagnostic Microbiology and Infectious Disease, March 1990, Elsevier

    Dr Steven Barriere

  36. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure

    Article • Clinical Pharmacology & Therapeutics, May 1989, Springer Science + Business Media

    Dr Steven Barriere

  37. Formulary activities: Notes from the P&T committee consideration of the impact of new oral antimicrobial agents

    Article • Antimicrobic Newsletter, June 1988, Elsevier

    Dr Steven Barriere

  38. The serum bactericidal test for evaluation of new antimicrobials and antimicrobial combinations

    Article • Antimicrobic Newsletter, October 1987, Elsevier

    Dr Steven Barriere

  39. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis

    Article • Journal of Antimicrobial Chemotherapy, January 1987, Oxford University Press (OUP)

    Dr Steven Barriere

  40. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve

    Article • Journal of Antimicrobial Chemotherapy, January 1985, Oxford University Press (OUP)

    Dr Steven Barriere

  41. Amdinocillin pharmacokinetics

    Article • The American Journal of Medicine, August 1983, Elsevier

    Dr Steven Barriere

  42. High-performance liquid chromatographic determination of cefmenoxime (AB-50912) in human plasma and urine

    Article • Journal of Chromatography B Biomedical Sciences and Applications, January 1983, Elsevier

    Dr Steven Barriere

  43. Nephrotoxicity of Cephalothin-Aminoglycoside Interactions

    Article • Archives of Internal Medicine, September 1982, American Medical Association (AMA)

    Dr Steven Barriere

  44. Utilization of antibiotics: Analysis of appropriateness of use

    Article • Annals of Emergency Medicine, August 1982, Elsevier

    Dr Steven Barriere

  45. Successful Treatment of Gram-negative Bacillary Meningitis with Moxalactam

    Article • Neurosurgery, June 1982, Wolters Kluwer Health

    Dr Steven Barriere

  46. High Pressure Liquid Chromatographic Determination of Mecillinam in Human Plasma and Urine

    Article • Analytical Letters, January 1981, Taylor & Francis

    Dr Steven Barriere

  47. Case Report Emergence of multiple antibiotic resistance during the therapy of Klebsiella pneumoniae meningitis

    Article • The American Journal of the Medical Sciences, January 1980, Elsevier

    Dr Steven Barriere